Advanced Renal Cell Carcinoma - Pipeline Insight, 2021
This report can be delivered to the clients within 3-5 business days
DelveInsight’s, “Advanced Renal Cell Carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Renal cell carcinoma is the most common type of kidney cancer. It usually starts as a tumor in one of your kidneys. And like other cancers, it can spread to other parts of your body. That’s when doctors call it metastatic. As the tumor grows, it spreads into fat or major blood vessels around the kidney. It may also creep into the adrenal gland, which sits right on top of the organ. Kidney cancer most often spreads to the lungs and bones, but it can also go to the brain, liver, ovaries, and testicles. The process used to find out if cancer has spread within the kidney or to other parts of the body is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order to plan treatment. The following tests and procedures may be used in the staging process: CT scan; MRI (magnetic resonance imaging); Chest x-ray; and bone scan. Different types of treatments are available for patients with renal cell cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials.
'Advanced Renal Cell Carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Advanced Renal Cell Carcinoma Emerging Drugs Chapters
This segment of the Advanced Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Renal Cell Carcinoma Emerging Drugs
Further product details are provided in the report.
Advanced Renal Cell Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Renal Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Advanced Renal Cell Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Renal Cell Carcinoma drugs.
Advanced Renal Cell Carcinoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Advanced Renal Cell Carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Renal cell carcinoma is the most common type of kidney cancer. It usually starts as a tumor in one of your kidneys. And like other cancers, it can spread to other parts of your body. That’s when doctors call it metastatic. As the tumor grows, it spreads into fat or major blood vessels around the kidney. It may also creep into the adrenal gland, which sits right on top of the organ. Kidney cancer most often spreads to the lungs and bones, but it can also go to the brain, liver, ovaries, and testicles. The process used to find out if cancer has spread within the kidney or to other parts of the body is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order to plan treatment. The following tests and procedures may be used in the staging process: CT scan; MRI (magnetic resonance imaging); Chest x-ray; and bone scan. Different types of treatments are available for patients with renal cell cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials.
'Advanced Renal Cell Carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Renal Cell Carcinoma.
Advanced Renal Cell Carcinoma Emerging Drugs Chapters
This segment of the Advanced Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Renal Cell Carcinoma Emerging Drugs
- Atezolizumab: Roche
- Bempegaldesleukin (NKTR-214): Nektar Therapeutics
Further product details are provided in the report.
Advanced Renal Cell Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Renal Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Advanced Renal Cell Carcinoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Advanced Renal Cell Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Renal Cell Carcinoma drugs.
Advanced Renal Cell Carcinoma Report Insights
- Advanced Renal Cell Carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Advanced Renal Cell Carcinoma drugs?
- How many Advanced Renal Cell Carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Renal Cell Carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Renal Cell Carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Advanced Renal Cell Carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Roche
- Nektar Therapeutic
- MedImmune LLC
- CoImmune
- X4 Pharmaceuticals
- Daiichi Sankyo, Inc.
- Eli Lilly and Company
- Jiangsu HengRui Medicine Co., Ltd.
- Allogene Therapeutics
- Apexigen, Inc.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Aravive, Inc.
- Arrowhead Pharmaceuticals
- Merck
- Apollomics
- Astex Pharmaceuticals
- Peloton Therapeutics, Inc.
- Infinity Pharmaceuticals
- Surface Oncology
- AO GENERIUM
- CRISPR Therapeutics AG
- Atezolizumab
- Bempegaldesleukin
- MEDI5752
- CMN-001
- X4P-001
- PT2385
- GNR-051
- CTX130
- Guadecitabine
- SRF388
- ARO-HIF2
- DS-6000a
- Abemaciclib
- SHR-1210
- ALLO-316
- APX005M
- TQB2450
- AVB-S6-500
- APL-501
- IPI-549
Introduction
Executive Summary
Advanced Renal Cell Carcinoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Atezolizumab: Roche
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
Guadecitabine: Astex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
MEDI5752: MedImmune
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Advanced Renal Cell Carcinoma Key Companies
Advanced Renal Cell Carcinoma Key Products
Advanced Renal Cell Carcinoma- Unmet Needs
Advanced Renal Cell Carcinoma- Market Drivers and Barriers
Advanced Renal Cell Carcinoma- Future Perspectives and Conclusion
Advanced Renal Cell Carcinoma Analyst Views
Advanced Renal Cell Carcinoma Key Companies
Appendix
Executive Summary
Advanced Renal Cell Carcinoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Atezolizumab: Roche
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
Guadecitabine: Astex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
MEDI5752: MedImmune
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Advanced Renal Cell Carcinoma Key Companies
Advanced Renal Cell Carcinoma Key Products
Advanced Renal Cell Carcinoma- Unmet Needs
Advanced Renal Cell Carcinoma- Market Drivers and Barriers
Advanced Renal Cell Carcinoma- Future Perspectives and Conclusion
Advanced Renal Cell Carcinoma Analyst Views
Advanced Renal Cell Carcinoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Advanced Renal Cell Carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Advanced Renal Cell Carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Advanced Renal Cell Carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Advanced Renal Cell Carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products